Aktie A3CTND BRII BIOSCIENCES LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Brii Biosciences Limited

Aktien

A3CTND

KYG1645A1094

2137

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:20 26.04.2024 		% 5 Tage % 1. Jan.
1,16 HKD +6,42 % Intraday Chart für Brii Biosciences Limited +11,54 % -49,12 %
25.03. Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024
22.03. Brii Biosciences Limited berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179
VBI Vaccines Sells Rights to Hepatitis B Vaccine to Brii Biosciences
Brii Biosciences to Buy Rights to Hepatitis B Vaccine from VBI
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Brii Biosciences Hires Chief Scientific Officer
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
Brii Biosciences Presents Hepatitis B Treatment Data at US Liver Disease Conference
PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 in Combination with PEG-IFN for the Treatment of Chronic Hepatitis B
Brii Biosciences’ Study Into Therapeutic Vaccine for Chronic Hepatitis B Patients Shows Safety, Tolerability
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating Brii-179 (Vbi-2601) in Combination with Peg-Ifn for the Treatment of Chronic Hepatitis B
Brii Biosciences Limited Announces Data from Interim Analysis of A Randomized, Placebo-Controlled and Double-Blinded Phase 2 Study of Brii-179
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
Brii Biosciences Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Shionogi Inc. completed the acquisition of Qpex Biopharma, Inc. from Brii Biosciences Limited and Others.
Brii Biosciences Collaborates with VBI Vaccines for Hepatitis B Project
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3CTND Aktie
  4. Nachrichten Brii Biosciences Limited
  5. Andere Sprachen